"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...

This approval introduces a subcutaneous (SC) injection option for patients with relapsing multiple sclerosis ... in the treatment of MS, particularly benefiting centers without IV infrastructure ...

Médunik Canada, a pharmaceutical company specializing in treatments for rare and debilitating diseases and part of Duchesnay Pharmaceutical Group (DPG), and the Population Council, a leading ...

Today is an important day for Cardarelli as it inaugurates a department dedicated to patients with multiple sclerosis. We ...

While it's possible for some DMTs to be infused at home, most people choose to come to the RUSH Multiple Sclerosis Center. The oldest and largest MS treatment center in the region, the center has ...